Joseph S. Tash, Ph.D.

Professor
University of Cambridge, England, 1977


Research Focus

Reproduction – male contraceptive drug development; space flight impacts on male and female reproductive health

Research Interests

The overall research goals in my lab comprise two major areas of reproductive science. The first main goal is to develop reversible non-hormonal male contraceptives and bring them to clinical trials. We have developed one lead compound that is an oral potent non-hormonal inhibitor of sperm maturation and release in the testis causing 100% infertility and complete recovery in male rats. Our research is elucidating the novel mechanism of action via disruption of actin bundles at the specialized junctions that tether spermatids to Sertoli cells. This advanced compound, H2-gamendazole (US Patent) is now under FDA guidance in preclinical development.  The second project is discovering novel potent inhibitors of the cell cycle CDK's (cyclin-dependent kinases) in the testis. These research projects are funded by two NIH U01 grants.

Our second major area of research, funded by multiple NASA grants, is elucidating the impact of long term space flight on male and female reproductive health.  One of our flight grants will determine the effect of space flight on sperm capacitation and signal transduction changes compared to parallel samples on the ground.  Our second flight grant will be one of the first flights to the International Space Station (ISS) with live animal return to determine if our previously identified discovery that space flight blocks follicle maturation is reversible.

Selected Recent Publications

Ronca AE, Baker ES, Bavendam TG, Beck KD, Miller VM, Tash JS, Jenkins M. Effects of Sex and Gender on Adaptation to Space: Reproductive Considerations. J Womens Health (Larchmt) 2014:In press.  

Schonbrunn E, Betzi S, Alam R, Martin MP, Becker A, Han H, Francis R, Chakrasali R, Jakkaraj S, Kazi A, Sebti SM, Cubitt CL, Gebhard AW, Hazlehurst LA, Tash JS, Georg GI. Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases. J Med Chem 2013; 56:3768-3782.

Tash JS, Chakrasali R, Jakkaraj SR, Hughes J, Smith SK, Hornbaker K, Heckert LL, Ozturk SB, Hadden MK, Kinzy TG, Blagg BS, Georg GI. Gamendazole, an orally active indazole carboxylic acid male contraceptive agent, targets HSP90AB1 (HSP90BETA) and EEF1A1 (eEF1A), and stimulates Il1a transcription in rat Sertoli cells. Biol Reprod 2008; 78:1139-1152.

Last modified: Oct 07, 2014

Contact

Joseph S. Tash, Ph.D.
Professor

Mailstop 3050
3901 Rainbow Boulevard
Kansas City, KS 66160

P: 913-588-7421
jtash@kumc.edu

ID=x6578